Marinus Pharmaceuticals Inc
Key Risks Facing Marinus Pharmaceuticals in December 2017
Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.
Why Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.
Ganaxalone Faces Stiff Competition from Other Drugs under Development
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected in 2018.
Why Ganaxalone Is a Promising Drug Candidate
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017.